Other Asia comprises all Asian territories excluding China and Japan. Anaesthetics make up 36% of revenue in these countries and territories, followed by several products in the Other Commercial Pharmaceutical brands category. We have active trading subsidiaries in the Philippines, Taiwan and Malaysia.
Key Countries and Territories
Contribution to Group revenue
Revenue contribution - by therapeutic category
- The Philippines pharmaceutical sector grew 6,9% and was valued at USD3,4 billion as at 30 June 2017.
- The Taiwan pharmaceutical sector grew 0,5% and was valued at USD5,4 billion as at 30 June 2017.
- The Indonesian pharmaceutical sector grew 0,3% and was valued at USD3,6 billion as at 30 June 2017.
Source: June 2017 IMS
Number of products launched:
IMS value of pipeline as at 30 June 2017 anticipated to be launched in:
0 – 2 years
3 – 5 years
Number of product recalls:
Average staff turnover:
Number of work-related fatalities:
Number of permanent employees:
|Revenue – R’billion||2017||2016 (CER)*||% change|
|High Potency & Cytotoxics||0,3||0,3||(3)|
|Other Commercial Pharmaceutical Brands||0,3||0,4||(7)|
* Constant exchange rate: FY16 restated at FY17 average exchange rates.
Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture.